Day One Biopharmaceuticals (DAWN) Expected to Announce Quarterly Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN) is expected to announce its earnings results after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Day One Biopharmaceuticals Trading Up 1.6 %

Shares of DAWN stock opened at $12.43 on Friday. Day One Biopharmaceuticals has a 1-year low of $11.13 and a 1-year high of $18.07. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -12.07 and a beta of -1.46. The stock’s fifty day simple moving average is $12.37 and its 200-day simple moving average is $13.47.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on DAWN shares. Bank of America lowered their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. The Goldman Sachs Group lowered their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research note on Monday, February 10th. Needham & Company LLC restated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other news, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. This represents a 10.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the sale, the insider now owns 1,034,015 shares of the company’s stock, valued at approximately $13,762,739.65. This trade represents a 2.82 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,064 shares of company stock worth $651,225. 8.40% of the stock is owned by corporate insiders.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.